India Pharma Outlook Team | Monday, 21 September 2026
Regulators on both sides of the Atlantic cleared sharper paths for new treatments today.
The European Medicines Agency’s CHMP delivered a positive opinion on Merck’s Keytruda-Padcev combination for muscle-invasive bladder cancer.
The FDA approved, and Amneal launched its lanreotide injection under Competitive Generic Therapy designation.
Meanwhile, India rewires its own machinery. The Drugs Consultative Committee weighs central licensing for all sterile drugs, and the Drugs Controller General of India advances a digital regulatory system plus 1,500 new CDSCO posts.
These moves share one theme: the EU and US accelerate finer, faster approvals while India builds the capacity and digital backbone to police quality and licensing more tightly.
Merck and Amneal illustrate how mature regulators now segment approvals by patient need and competitive gap. A CHMP positive opinion signals scientific endorsement that the European Commission normally converts into a binding marketing authorization within months.
For Merck, the recommendation extends Keytruda-Padcev to cisplatin-eligible patients after earlier approval for the cisplatin-ineligible group, creating a broader perioperative option regardless of chemotherapy eligibility.
Across the Atlantic the FDA granted Amneal Competitive Generic Therapy designation for its lanreotide injection, a long-acting treatment for acromegaly, GEP-NETs and carcinoid syndrome. CGT designation rewards the first approved generic of a drug with limited competition and can confer 180 days of exclusivity.
Amneal’s immediate launch, backed by in-house manufacturing, shows how the pathway speeds complex injectable generics into a market previously dominated by a single branded product.
India confronts a different challenge. Sterile injectables and ophthalmics remain highly vulnerable to microbial contamination. Around 240 injection samples tested not of standard quality in 2025-26, and recent international alerts cited Burkholderia cepacia in metoprolol and Gram-negative bacteria in adenosine.
Today only large-volume parenterals, vaccines, sera and certain advanced biologics fall under the Central Licensing Approving Authority. State drug controllers still license most other sterile products.
The proposal now before the Drugs Consultative Committee seeks to place every sterile formulation under central oversight, arguing that fragmented scrutiny and post-license product additions produce inconsistent inspection standards. The move would transfer primary licensing authority from state controllers to CDSCO while states retain enforcement roles under Chapter IV of the Drugs and Cosmetics Act.
Also Read: How Biologics and Complex Therapies Are Reshaping CDMO Strategy
Central licensing only works if the regulator possesses inspection depth and data systems. DCGI Dr Rajeev Singh Raghuvanshi confirmed a proposal for 1,500 new scientific posts to strengthen in-house review, audit and inspection capacity.
Parallel to staffing, twelve companies have completed technical presentations for a new digital regulatory platform that will embed AI and analytics.
The same office is building a quality surveillance database that already adds roughly 200 products each month; procurement agencies will gain access so they can factor quality history into tender decisions. Together, these steps aim to give central sterile licensing the operational backbone it currently lacks.
Sterile and injectable manufacturers face higher uniformity requirements and potentially longer central review timelines once the DCC recommendation advances. Contract manufacturers that supply both domestic and export markets will need to align documentation and site readiness with a single national standard.
Procurement teams gain a practical tool in the expanding quality database. Indian firms targeting US injectable approvals continue to benefit from CGT-style pathways abroad while preparing for tighter domestic sterile oversight at home.
The European Commission decision on Keytruda-Padcev in Q4 2026, the DCC’s formal recommendation on sterile licensing, award and go-live of the digital regulatory system, and the timeline for filling the 1,500 CDSCO posts will determine how quickly these parallel tracks reshape the regulatory on-ramp.
.jpg)
